Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma
Potnis K, Huntington S. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma. Blood Advances 2023, 7: 2573-2574. PMID: 36745098, PMCID: PMC10242627, DOI: 10.1182/bloodadvances.2023009864.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, Murine-DerivedCost-Benefit AnalysisCost-Effectiveness AnalysisHumansLymphoma, FollicularRituximabCost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Bewersdorf J, Huntington S, Zeidan A. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? Journal Of The National Comprehensive Cancer Network 2023, 21: 522-528. PMID: 37037494, DOI: 10.6004/jnccn.2023.70012.Peer-Reviewed Original ResearchMeSH KeywordsAdultCost-Benefit AnalysisCost-Effectiveness AnalysisHumansLeukemia, Myeloid, AcutePatient CareUnited StatesConceptsCost-effectiveness analysisEconomic modeling techniquesCost-effectiveness studiesFinite financial resourcesDrug pricesHealth policy decisionsPolicy decisionsFinancial resourcesResource allocationUnited StatesPublic interestCostHealthcare systemPricesSuch analysesLimited resourcesAllocationCountriesConsumersData sourcesPayersAssumptionBenefitsBudgetary considerationsDifferent interventions